Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 30Other hematologic neoplasm 25Lymphoid 21Gastrointestinal 13Gynecologic 12Genitourinary 11Breast 10Thoracic 8Plasma cell 8Myeloid 6Sarcoma 3Head & Neck 3Other solid neoplasm 2CNS 2Tumor-Agnostic 1NET 1Endocrine 1

Conditions

Urogenital Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

lutetium Lu 177 dotatate 7Specimen Handling 7Magnetic Resonance Spectroscopy 7gallium Ga 68 dotatate 3cabozantinib 3X-Rays 3Everolimus 3Sunitinib 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2romidepsin 1peposertib 1pembrolizumab 1pazopanib 1olaparib 1fludarabine 1belinostat 1aldesleukin 1Sorafenib 1Salts 1Photons 1Octreotide 1Nivolumab 1Lactones 1Ipilimumab 1Introns 1Interferon alpha-2 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × fludarabine × NET × Clear all
NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡